Skip to content

Placenta Accreta Spectrum Outcome After Uterine Conservation

Short and Intermediate Term Outcomes of Uterine Conservation After Cesarian Section in Cases of Placenta Accreta Spectrum

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04866888
Acronym
PAS
Enrollment
120
Registered
2021-04-30
Start date
2021-04-28
Completion date
2026-03-15
Last updated
2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placenta Accreta Spectrum

Keywords

PAS

Brief summary

study will be carried out on patients with placenta accreta spectrum having done uterine conservation and recording immediate outcome of conservation regarding success of the procedure, amount of blood loss and amount of blood transfused and followed up to check the return of menses, any uterine abnormalities by ultrasound or hysteroscopy especially isthmocele and intrauterine synechia.

Detailed description

After institutional review board approval and written informed consent, recruited cases will be subjected to the following: 1. Data registration including: * Age. * Obstetric history including gravidity, parity, number of previous cesarean deliveries, and number and gender of living children. * Details of the current pregnancy including duration in menstrual weeks, any problems encountered during its course. * Desire for future fertility. * Medical, surgical, and medication history. 2. Anthropometry including weight, height, and body mass index (BMI) before pregnancy and at the time of operation. 3. General examination including vital signs, and signs of any associated problems. 4. Routine laboratory investigations with particular emphasis on complete blood count, Coagulation profile and including blood glucose level, renal and liver function tests. 5. Detailed sonographic examination to evaluate fetal biometry, and wellbeing rule out exclusion factors, and confirm diagnosis of PAS and assess the degree of invasion, and its severity using both trans-abdominal transducer with frequency of 2-5 megahertz (MHZ) and trans-vaginal transducer with frequency of 4-10 MHZ. Intraoperative details will be documented. Follow up of patients will be recorded. Sample size was calculated by estimating a single proportion distribution at a significance level of 0.05.

Interventions

PROCEDUREclosure of the uterine wall defect

Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally.

DIAGNOSTIC_TESTultrasound

Before the procedure transabdominal and transvaginal ultrasound will be done to diagnose PAS and to map the uterine wall defects. After 3 months,Transabdominal and transvaginal ultrasound with different modalities to assess the uterine wall, the cavity, endometrium, myometrium and the cervix. Isthmocele will be defined as a defect at uterine wall where residual myometrium thickness and ratio between residual myometrium and total myometrium thickness will be measured and recorded. The shape of the isthmocele will be also recorded.

Office hysteroscope will be done after patient consent to evaluate the uterine cavity if the patient is symptomatic or with abnormal sonography. It will be performed in the proliferative phase of the menstrual cycle. Non-steroidal anti-inflammatory will be given one hour before the procedure, then the patient will be in lithotomy position. Following aseptic rules, the rigid 4 mm hysteroscope will be inserted into the uterus through the cervix without using speculum nor tenaculum. Any pathology will be identified, and data will be recorded.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Uterus will be incised 5mm above the placenta bulge. Uterine exteriorization followed by pealing of amniotic membranes to reach an accessible pole of the placenta to detect a plan of cleavage behind it. The independent hand of the surgeon passed through the previous plan from points of least resistance to high resistance. The defect will be repaired from the inner aspect of the uterus via running sutures using Vicryl (1-0) on a round needle, 45mm. the suture will pass from one edge to hitch the bed and pass to the other edge till we completely close the defect subsequently, controlling the bleeding. Uterine scar closure by running sutures in two layers, where the first layer compresses the placental bed defect externally. After 3 months ultrasound and out-patient hysteroscopy will be done to check for any uterine abnormalities

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* • Diagnosed sonographically to have placenta accreta spectrum. * Pregnancy is singleton and fetus is alive. * Elective caesarean section done from 35 gestational weeks.

Exclusion criteria

* • Patients requesting hysterectomy. * Coexisting uterine pathology such as fibroids or gynaecological malignancies. * Patients with bleeding diathesis. * Morbid obesity of BMI \>40. * Patients having labour pains or vaginal bleeding before scheduled intervention.

Design outcomes

Primary

MeasureTime frameDescription
date of resumed mensesfrom 2 weeks to 6 months after surgerycalculate the duration from surgery until menses returns
menstrual abnormalitiesfrom 2 to 6 months after surgeryrecord type of menstrual abnormalities if present such as amenorrhea, oligomenorrhea and dysmenorrhea
abnormal uterine bleedingfrom 2 to 6 months after surgeryrecord the presence of abnormal uterine bleeding after the return of menses such as intermenstrual bleeding, menorrhagia
pelvic painfrom 2 to 6 months after surgeryrecord the presence of pelvic pain and its duration
isthmocelefrom 3 to 6 months after surgerytrans-vaginal and trans-abdominal ultrasound will be done to record the presence of isthmocele, its shape and ratio between residual myometrium and total myometrium
intrauterine adhesionsfrom 3 to 6 months after surgeryoutpatient hysteroscopy will be done to symptomatic patients after consent in order to check uterine cavity recording the presence of intrauterine adhesions, and categorization of adhesions according to american fertility society into mild, moderate and severe
puerperal blood loss48 hours until 2 months after surgeryrecording the duration of blood loss during puerperium and average number of tampons changed per day
contraception useintraoperative until 5 months after surgeryrecording method of contraception used
fibrosisfrom 3 to 6 months after surgerygrey scale ultrasound will be done to record size of intra-myometrium fibrosis

Secondary

MeasureTime frameDescription
urine outputintraoperativerecording amount of urine output
internal iliac artery ligationintraoperativerecording if the internal iliac artery ligated whether it was unilateral or bilateral
pre-operative hemoglobinpreoperativerecording amount of hemoglobin
post-operative hemoglobinpostoperative within 6 hours from surgeryrecording amount of hemoglobin
operation timeintraoperativerecording total time of the surgery
ICU admissionimmediate postoperative until 5 days after surgeryrecording the number of patients admitted to the ICU
intermediate care admissionrecording the number of patients admitted to the ICUrecording the number of patients admitted to the intermediate care
surgical diagnosisintraoperativedocument the type of placenta accreta spectrum whether it is accreta, increta or percreta and area of the uterus where the placental invade
hospital staypostoperative until 10 days after surgeryrecording duration of hospital stay after surgery
repair timeintraoperativerecording length of defect repair from placental separation until uterine wall closure
Estimated blood lossintraoperativerecording amount of blood loss
packed red blood cells transfusionintraoperative until 24 hours after surgeryrecording amount of red blood cell transfused
fresh frozen plasma (FFP) transfusionintraoperative until 24 hours postoperativerecording amount of FFP transfusion
bladder injuryintraoperative until 2 weeks post operativerecording if there was an injury to the bladder
ureter injuryintraoperative until 2 weeks post operativerecording if there was an injury to the ureter
bowel injuryintraoperative until 2 weeks post operativerecording if there was an injury to the bowel
surgical site infection24 hours until 1 month after surgeryrecord the presence of wound infection

Countries

Egypt

Contacts

Primary ContactOmar Y Elshorbagy, As.lec
o_kamal13@alexmed.edu.eg01111362322

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026